nach oben

Cancer Chemotherapy and Pharmacology

Erschienen in:

01.08.2008 | Original Article

4-Aryl-1,3,2-oxathiazolylium-5-olate: a novel GST inhibitor to release JNK and activate c-Jun for cancer therapy

verfasst von: Huifei Cui, Jie Shen, Dongning Lu, Tao Zhang, Wenpeng Zhang, Duxin Sun, Peng George Wang

Erschienen in: Cancer Chemotherapy and Pharmacology | Ausgabe 3/2008

Einloggen, um Zugang zu erhalten

Abstract

Purpose

The over-expression of glutathion S-transferase Pi (GSTπ) in tumors and inhibitory effect of GSTπ to JNK are two possible causes of the development of drug-resistance in chemotherapy. This research is to develop a novel pH-controlled NO donor to inhibit GSTπ(and to activate the JNK/c-Jun pathway (omit “to induce apoptosis”).

Methods

Four 4-Aryl-1,3,2-oxathiazolylium-5-olate (OZO) derivatives with varying aryl para-substitutions (–H, –CF₃, –Cl, and –OCH₃) were synthesized. Anticancer activity was determined by MTS assay. GST activity was measured with spectrophotometry using 1-chlro-2,4-dinitrobenzene (CDNB) and GSH as substrates. (omit “Apoptosis was evaluated by annexin V staining and flow cytometry”). c-Jun N-terminal kinase 1 (JNK1) association with GSTπ and activation of c-Jun were evaluated with immunoprecipitation and western blot.

Results

OZO derivatives showed anticancer effect against leukemia and breast cancer cells by MTS assay. The relative potency of their anticancer effects is OZO-H > OZO-Cl, OZO-OMe > OZO-CF₃. The anticancer activity of these compounds was correlated with their inhibition of GST activity in cancer cells. The immunoprecipitaion result showed that the treatment of OZO-H released JNK1 from GSTπ-JNK1 complex. Consequently, the treatment of OZO-H in cancer cells induced JNK1 phophorylation and activated c-Jun in cancer cells.

Conclusion

OZO-H is a novel GST inhibitor to release JNK1 for activation of JNK/c-Jun pathway (original is “c-Jun to trigger apoptosis in cancer cells”). It provides a new class of GST target compound for anticancer therapy.

Alemagna A, Bacchetti T (1976) 4-Phenyl-1,3,2-oxathiazol-5-one. III: unusual sulfenamidic derivatives from the reaction with thiolates. Chimica e l’Industria (Milan, Italy) 58:616–617

Armstrong RN (1997) Structure, catalytic mechanism, and evolution of the glutathione transferases. Chem Res Toxicol 10:2–18PubMedCrossRef

Adler V, Yin Z, Fuchs SY et al (1999) Regulation of JNK signaling by GSTpi. EMBO J 18:1321–1334PubMedCrossRef

Boesgaard S, Aldershvile J, Poulsen HE et al (1994) Nitrate tolerance in vivo is not associated with depletion of arterial or venous thiol levels. Circ Res 74:115–120PubMed

Burg D, Filippov Dmitri V, Hermanns R et al (2002) Peptidomimetic glutathione analogues as novel gammaGT stable GST inhibitors. Bioorg Med Chem 10:195–205PubMedCrossRef

Burg D, Mulder GJ (2002) Glutathione conjugates and their synthetic derivatives as inhibitors of glutathione-dependent enzymes involved in cancer and drug resistance. Drug Metab Rev 34:821–863PubMedCrossRef

Burg D, Riepsaame J, Pont C, Mulder G, van de Water B (2006) Peptide-bond modified glutathione conjugate analogs modulate GSTp function in GSH-conjugation, drug sensitivity and JNK signaling. Biochem Pharmacol 71:268–277PubMedCrossRef

Ciaccio PJ, Shen H, Jaiswal AK et al (1995) Modulation of detoxification gene expression in Human colon HT29 cells by glutathione-S-transferase inhibitors. Mol Pharmacol 48:639–647PubMed

Davis RJ (2000) Signal transduction by the JNK group of MAP kinases. Cell 103:239–252PubMedCrossRef

10.

Fan M, Chambers TC (2001) Role of mitogen-activated protein kinases in the response of tumor cells to chemotherapy. Drug Resist Updat 4:253–267PubMedCrossRef

11.

Filomeni G, Aquilano K, Rotilio G et al (2003) Reactive oxygen species-dependent c-jun NH2-terminal kinase/c-Jun signaling cascade mediates neuroblastoma cell death induced by diallyl disulfide. Cancer Res 63:5940–5909PubMed

12.

Flatgaard JE, Bauer KE, Kauvar LM (1993) Isozyme specificity of novel glutathione-S-transferase inhibitors. Cancer Chemother Pharmacol 33:63–70PubMedCrossRef

13.

Govoni M, Casagrande S, Maucci R et al (2006) In vitro metabolism of (nitrooxy)butyl ester nitric oxide-releasing compounds: comparison with glyceryl trinitrate. J Pharmacol Exp Ther 317:752–761PubMedCrossRef

14.

Habig WH, Jakoby WB (1981) Assays for differentiation of glutathione S-transferases. Methods Enzymol 77:398–405PubMed

15.

Hamilton D, Batist G (2005) TLK-199 Telik. IDrugs 8:662–669PubMed

16.

Hansson J, Berhane K, Castro VM et al (1991) Sensitization of human melanoma cells to the cytotoxic effect of melphalan by the glutathione transferase inhibitor ethacrynic acid. Cancer Res 51:94–98PubMed

17.

Kauvar LM, Morgan AS, Sanderson PE et al (1998) Glutathione based approaches to improving cancer treatment. Chem Biol Interact 111:225–238PubMedCrossRef

18.

Lemercier J-N, Meier BW, Gomez JD et al (2004) Inhibition of glutathione S-transferase P1-1 in mouse lung epithelial cells by the tumor promoter 2,6-Di-tert-butyl-4-methylene-2,5-cyclohexadienone (BHT-Quinone Methide): protein adducts investigated by electrospray mass spectrometry. Chem Res Toxicol 17:1675–1683PubMedCrossRef

19.

Lu DN, Nadas J, Zhang GS et al (2007) 4-Aryl-1,3,2-oxathiazolylium-5-olates as pH-controlled NO-donors: the next generation of S-nitrosothiols. J Am Chem Soc 129:5503–5514PubMedCrossRef

20.

Lyttle MH, Satyam A, Hocker MD et al (1994) Glutathione-S-transferase activates novel alkylating agents. J Med Chem 37:1501–1507PubMedCrossRef

21.

Mahajan S, Atkins WM (2005) The chemistry and biology of inhibitors and pro-drugs targeted to glutathione S-transferases. Cell Mol Life Sci 62:1221–1233PubMedCrossRef

22.

Mantle TJ, Parraga A, Vega MC et al (2000) Studies on the reaction mechanism of mouse liver glutathione S-transferase P1-1. Clin Chem Enzymol Commun 8:223–230

23.

Morgan AS, Ciaccio PJ, Tew KD et al (1996) Isozymespecific glutathione S-transferase inhibitors potentiate drug sensitivity in cultured human tumor cell lines. Cancer Chemother Pharmacol 37:363–370PubMedCrossRef

24.

Morgan AS, Sanderson PE, Borch RF et al (1998) Tumor efficacy and bone marrow-sparing properties of TER286, a cytotoxin activated by glutathione S-transferase. Cancer Res 58:2568–2575PubMed

25.

Nagourney RA, Messenger JC, Kern DH et al (1990) Enhancement of anthracycline and alkylator cytotoxicity by ethacrynic acid in primary cultures of human tissues. Cancer Chemother Pharmacol 26:318–322PubMedCrossRef

26.

O’Brien ML, Tew KD (1996) Glutathione and related enzymes in multidrug resistance. Eur J Cancer 32:967–978CrossRef

27.

Ono K, Han J (2000) The p38 signal transduction pathway: activation and function. Cell Signal 12:1–13PubMedCrossRef

28.

Ploemen JH, van Ommen B, van Bladeren PJ (1990) Inhibition of rat and human glutathione S-transferase isoenzymes by ethacrynic acid and its glutathione conjugate. Biochem Pharmacol 40:1631–1635PubMedCrossRef

29.

Potapova O, Haghighi A, Bost F et al (1997) The Jun kinase/stress-activated protein kinase pathway functions to regulate DNA repair and inhibition of the pathway sensitizes tumor cells to cisplatin. J Biol Chem 272:14041–14044PubMedCrossRef

30.

Ralat LA, Colman RF (2003) Monobromobimane occupies a distinct xenobiotic substrate site in glutathione S-transferase p. Protein Sci 12:2575–2587PubMedCrossRef

31.

Ricci G, De Maria F, Antonini G et al (2005) 7-Nitro-2,1,3-benzoxadiazole derivatives, a new class of suicide inhibitors for glutathione S-transferases: mechanism of action of potential anticancer drugs. J Biol Chem 280:26397–26405PubMedCrossRef

32.

Ricci G, Caccuri AM, Lo Bello M et al (1996) Structural flexibility modulates the activity of human glutathione transferase P1-1. Role of helix 2 flexibility in the catalytic mechanism. J Biol Chem 271:16187–16192PubMedCrossRef

33.

Schultz M, Dutta S, Tew KD (1997) Inhibitors of glutathione S-transferases as therapeutic agents. Adv Drug Deliv Rev 26:91–104PubMedCrossRef

34.

Tellez-Sanz R, Cesareo E, Nuccetelli M et al (2006) Calorimetric and structural studies of the nitric oxide carrier S-nitrosoglutathione bound to human glutathione transferase P1-1. Protein Sci 15:1093–1105PubMedCrossRef

35.

Tew KD (2005) TLK-286: a novel glutathione S-transferase-activated prodrug. Expert Opin Investig Drugs 14:1047–1054PubMedCrossRef

36.

Tew KD, Bomber AM, Hoffman SJ (1988) Ethacrynic acid and piriprost as enhancers of cytotoxicity in Drug resistant and sensitive cell lines. Cancer Res 48:3622–3625PubMed

37.

Tew KD (1994) Glutathione-associated enzymes in anticancer drug resistance. Cancer Res 54:4313–4320PubMed

38.

Tew KD, Monks A, Barone L et al (1996) Glutathione-associated enzymes in the human cell lines of the National Cancer Institute Drug Screening Program. Mol Pharmacol 50:149–159PubMed

39.

Thatcher GRJ, Nicolescu AC, Bennett BM et al (2004) Nitrates and NO release: Contemporary aspects in biological and medicinal chemistry. Free Radic Biol Med 37:1122–1143PubMedCrossRef

40.

Townsend DM, Findlay VJ, Fazilev F et al (2006) A glutathione S-transferase p-activated prodrug causes kinase activation concurrent with S-glutathionylation of proteins. Mol Pharmacol 69:501–508PubMedCrossRef

41.

Townsend DM, Tew KD (2003) The role of glutathione-Stransferase in anti-cancer drug resistance. Oncogene 22:7369–75PubMedCrossRef

42.

Turella P, Cerella C, Filomeni G et al (2005) Proapoptotic activity of new glutathione S-transferase inhibitors. Cancer Res 65:3751–3761PubMedCrossRef

43.

Turella P, Filomeni G, Dupuis ML et al (2006) A strong glutathione S-transferase inhibitor overcomes the P-glycoprotein-mediated resistance in tumor cells: 6-(7-nitro-2,1,3-benzoxadiazol-4-ylthio)hexanol (NBDHEX) triggers a caspase-dependent apoptosis in MDR1-expressing leukemia cells. J Biol Chem 281:23725–23732PubMedCrossRef

44.

van Iersel MLPS, Ploemen J-PHTM, Lo Bello M et al (1997) Interactions of a,b-unsaturated aldehydes and ketones with human glutathione S-transferase P1-1. Chem Biol Interact 108:67–78PubMedCrossRef

45.

van Zanden JJ, Ben Hamman O, van Iersel MLPS et al (2003) Inhibition of human glutathione S-transferase P1-1 by the flavonoid quercetin. Chem Biol Interact 145:139–148PubMedCrossRef

46.

Vega MC, Walsh SB, Mantle TJ et al (1998) The three-dimensional structure of Cys-47-modified mouse liver glutathione S-transferase P1-1. Carboxymethylation dramatically decreases the affinity for glutathione and is associated with a loss of electron density in the aB-310B region. J Biol Chem 273:2844–2850PubMedCrossRef

47.

Wu Z, Minhas GS, Wen D et al (2004) Design, synthesis, and structure-activity relationships of haloenol lactones: site-directed and isozyme-selective glutathione S-transferase inhibitors. J Med Chem 47:3282–3294PubMedCrossRef

48.

Xu BH, Singh SV (1992) Effect of buthionine sulfoximine and ethacrynic acid on cytotoxic activity of Mitomycin C analogues BMY 25282 and BMY 25067. Cancer Res 52:6666–6670PubMed

49.

Yeates RA, Laufen H, Leitold M (1985) The reaction between organic nitrates and sulfhydryl compounds. A possible model system for the activation of organic nitrates. Mol Pharmacol 28:555–559PubMed

50.

Yin Z, Ivanov V, Habelhah H, et al (2000). Glutathione S-transferase pi elicits protection against H₂O₂-induced cell death via coordinated regulation of stress kinases. Cancer Res (Adv Brief) 60:4053–4057

51.

Zhao G, Wang X (2006) Advance in antitumor agents targeting glutathione-S-transferase. Curr Med Chem 13:1461–1471PubMedCrossRef

52.

Zheng J, Liu G, Tozkoparan B et al (2005) Mechanistic studies of inactivation of glutathione S-transferase Pi isozyme by a haloenol lactone derivative. Med Chem 1:191–198PubMed

Titel: 4-Aryl-1,3,2-oxathiazolylium-5-olate: a novel GST inhibitor to release JNK and activate c-Jun for cancer therapy
verfasst von: Huifei Cui
Jie Shen
Dongning Lu
Tao Zhang
Wenpeng Zhang
Duxin Sun
Peng George Wang
Publikationsdatum: 01.08.2008
Verlag: Springer-Verlag
Erschienen in: Cancer Chemotherapy and Pharmacology / Ausgabe 3/2008
Print ISSN: 0344-5704
Elektronische ISSN: 1432-0843
DOI: https://doi.org/10.1007/s00280-007-0632-3

Springer Medizin

4-Aryl-1,3,2-oxathiazolylium-5-olate: a novel GST inhibitor to release JNK and activate c-Jun for cancer therapy

Abstract

Purpose

Methods

Results

Conclusion

Neu im Fachgebiet Onkologie

Labor, CT-Anthropometrie zeigen Risiko für Pankreaskrebs

Viel pflanzliche Nahrung, seltener Prostata-Ca.-Progression

Alter verschlechtert Prognose bei Endometriumkarzinom

Darf man die Behandlung eines Neonazis ablehnen?

Update Onkologie

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2008

Polyamine catabolism in colorectal cancer cells following treatment with oxaliplatin, 5-fluorouracil and N 1 , N 11 diethylnorspermine

Topotecan and carboplatin in patients with platinum-sensitive recurrent ovarian cancer. Results of a multicenter NOGGO: phase I/II study

Tumor, tissue, and plasma pharmacokinetic studies and antitumor response studies of docetaxel in combination with 9-nitrocamptothecin in mice bearing SKOV-3 human ovarian xenografts

Logistic regression analysis for febrile neutropenia (FN) induced by docetaxel in Japanese cancer patients

The plasma and cerebrospinal fluid pharmacokinetics of erlotinib and its active metabolite (OSI-420) after intravenous administration of erlotinib in non-human primates

In vitro evaluation of the growth inhibition and apoptosis effect of mifepristone (RU486) in human Ishikawa and HEC1A endometrial cancer cell lines

Neu im Fachgebiet Onkologie

Labor, CT-Anthropometrie zeigen Risiko für Pankreaskrebs

Viel pflanzliche Nahrung, seltener Prostata-Ca.-Progression

Alter verschlechtert Prognose bei Endometriumkarzinom

Darf man die Behandlung eines Neonazis ablehnen?

Update Onkologie